[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)
date : 11/5/2020
Tags: AMR
AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) held a Roundtable on Medical Fee System Measures to Discourage the Spread of AMR.
This meeting was held on the basis of AMR Alliance Japan’s overarching policy recommendations published in July 2019 which called for the promotion of measures through the medical fee system to incentivize behaviors that could help to discourage the spread of antimicrobial resistance (AMR).
AMR Alliance Japan members discussed recommendations toward the 2022 revision of the medical fee system. Based on the discussion, AMR Alliance Japan decided on the key items to be targeted in future proposals on the medical fee system revision.
In light of the situation with novel coronavirus, this meeting was carried out primarily online.
■Overview
Date and time: Wednesday, September 28, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
Roundtable Discussion
・Key items for AMR Alliance Japan’s Medical Fee System Revision Proposal
・Future Plans
■Roundtable Speakers (alphabetical order by last name):
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Masashi Kawata (Senior Manager, Public Affairs & Policy, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Yuri Miura (Senior Industry Policy Specialist, Public and Industrial Policy, Health Policy, MSD K.K.)
Masaaki Miyakawa (Executive Board Member, Japan Medical Association)
Choichiro Miyazaki (Vice Chairman, Japan Pharmaceutical Association)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Toshiyuki Sakaeda (President, The Japanese Society of Therapeutic Drug Monitoring / Professor, Department of Pharmacokinetics, Kyoto Pharmaceutical University)
Makoto Seno (Marketing Director, Nippon Becton Dickinson Company Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
■Moderator:
Yuki Awano (AMR Alliance Japan Secretariat / Associate, HGPI)
Top Research & Recommendations Posts
- [Research Report] Energy Conservation and Greenhouse Gas Emissions Reduction in Healthcare Facilities: Case Studies from New Construction and Facility Renewal (March 16, 2026)
- [Public Comment Submission] “The 7th Science, Technology and Innovation Basic Plan” (Draft) (February 19, 2026)
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Dementia Project “The Future of Dementia Policy Surrounding Families and Others Who Care for People with Dementia” (April 27, 2026)
- [Research Report] A Nationwide Survey on Cancer in Japan: 20 Years Since the Enactment of the Cancer Control Act (April 28, 2026)
- [Research Report] The 2026 Public Opinion Survey on Healthcare in Japan (February 13, 2026)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] Signs Health Policy Recommendations to the G7 by the C7 Global Health Working Group (March 30, 2026)
Featured Posts
-
2026-05-13
[Registration Open] HGPI Salon 2025-2026 Looking Ahead to the Future of Japan’s Social Security System “Session 5: The Value of Healthcare in Society – Perspectives from the Reiwa Era” (June 29, 2026)
-
2026-05-15
[Registration Open] (Webinar) The 2nd J-PEP Seminar – A New Framework for Providing Information on Clinical Trial Participant Recruitment – Legal Points to Consider from the Perspective of Meaningful Involvement (June 15, 2026)
-
2026-05-18
[Registration Open] Kick-off Panel Discussion “From Japan and Africa, in Discussion with the World: Cultivating Together a Philosophical Dialogue on Health” (June 15, 2026)
-
2026-05-19
[Registration Open] (Webinar) HGPI Special Seminar “Building a Society Where People Live with Blood Disorders: The Future of Blood Disorder Policy as Examined from the Frontlines of Home-Based Care × Lived Experience Research” (June 12, 2026)



